On demand antimicrobial iodine in a wound contact matrix

Information

  • Research Project
  • 6403782
  • ApplicationId
    6403782
  • Core Project Number
    R44AI048353
  • Full Project Number
    2R44AI048353-02
  • Serial Number
    48353
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2001 - 23 years ago
  • Project End Date
    8/31/2003 - 21 years ago
  • Program Officer Name
    TSENG, CHRISTOPHER K.
  • Budget Start Date
    9/15/2001 - 23 years ago
  • Budget End Date
    8/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/10/2002 - 22 years ago
Organizations

On demand antimicrobial iodine in a wound contact matrix

DESCRIPTION (provided by applicant): Wound infection is the single-most important complication encountered in the management of chronic non-healing wounds. More than 10 million US patients per annum, at a cost of greater than $10 billion, receive treatment for chronic wounds. Microorganisms not only interfere with the wound healing process but use open areas as portals of entry for systemic infection. Current clinical strategies rely on the use of topical or systemic antibiotics for controlling wound bioburden. In Phase I we proposed studying the feasibility of incorporating wound exudate responsive chemistry capable of producing elemental iodine directly into a moist wound dressing material. Iodine is antimicrobial at non-toxic levels for tissue but is extremely unstable in its antimicrobial I2 form. Our proposal involved encapsulation of iodine precursors along with conversion chemistry directly into a well known wound contact material. The Phase I results found that signals commonly found in wound exudate fluid triggered the conversion of iodine precursors to antimicrobial elemental iodine. The Phase II studies are aimed at refining the chemistry of the reaction to provide greater control on the rates of production and sustained release of the iodine. Completion of these studies will yield a novel wound sensing antimicrobial dressing for controlling wound bioburden. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    496447
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:496447\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACRYMED, INC.
  • Organization Department
  • Organization DUNS
    878062256
  • Organization City
    BEAVERTON
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    97008
  • Organization District
    UNITED STATES